Weekender 10/23/15

Welcome to another edition of the Weekender.

A week of inspiration, hope, promising science and potential cures from New Jersey’s life sciences community…

BioNJ Member Cyclacel Pharmaceuticals announced the dosing of the first patient in a Phase 1 trial of CYC065, the company’s novel second generation CDK (cyclin-dependent kinase) 2/9 inhibitor, for the treatment of advanced solid tumors.

BioNJ Member Elusys Therapeutics announced it has been awarded $16 million of additional funding from the U.S. Government to further advance development of a lyophilized form of Anthim® (obiltoxaximab), an investigational agent for the treatment of inhalational anthrax infection following a biowarfare attack.

The National Institute of Neurological Disorders and Stroke (NINDS) has awarded BioNJ Member RUCDR Infinite Biologics, a unit of Rutgers’ Human Genetics Institute of New Jersey, a $6 million grant. RUCDR, which is located on Rutgers’ Busch Campus in Piscataway, is the world’s largest university-based biorepository.

In a study involving nearly 400 subjects, researchers from BioNJ Member Rowan University School of Osteopathic Medicine and Durin Technologies, have demonstrated that a blood test they developed can detect early-stage Parkinson’s disease.

Join us for BioNJ’s Entrepreneurship Program, Mission Possible: Non-Traditional Avenues to Funding Your Start-Up. Taking place next Thursday, October 29, at BioNJ Preferred Member Rutgers University, you’ll hear presentations and case studies on non-traditional and unique funding opportunities. Register now.

Click here to read this week’s Weekender.